The global immunoprotein diagnostic testing market size was valued at USD 10.39 billion in 2025 and is projected to grow from USD 11.07 billion in 2026 to USD 18.38 billion by 2034, registering a CAGR of 6.54% during the forecast period from 2026 to 2034. North America dominated the immunoprotein diagnostic testing market with a market share of 38.5% in 2025.
Immunoprotein Diagnostic Testing (ICI) refers to a specialized diagnostic approach that utilizes immunological methods to detect and analyze specific proteins in the body. These tests play a crucial role in diagnosing various conditions, including infectious and chronic diseases like cancer, by providing personalized results that guide appropriate treatment plans.
The major factors driving the growth of the ICI market include the rising prevalence of infectious and chronic diseases, such as cancer, advancements in screening technologies, a growing geriatric population, and the expansion of healthcare infrastructure. Cancer, being one of the most prevalent chronic diseases, is a major contributor to the market's expansion.
Moreover, the increasing number of cancer cases worldwide underscores the importance of immunoprotein diagnostics, which offer accurate, patient-specific diagnoses to ensure targeted and effective treatments. This has significantly boosted the demand for immunoprotein diagnostic testing, positioning it as a vital component in the global landscape.
Download a Free Sample To learn more about this report,
The increasing focus on discovering novel biomarkers for diagnosing diseases such as cancer and infectious diseases like tuberculosis is driving growth in the global immunoprotein diagnostic testing market. New, innovative approaches are emerging to accelerate the development of these biomarkers.
The ongoing adoption of these advanced strategies for biomarker development is significantly driving market growth and unlocking new opportunities in disease diagnosis.
Biosensors, which detect protein biomarkers to diagnose diseases, are becoming more advanced with the integration of artificial intelligence. AI-powered biosensors are making the diagnostic process more accurate, efficient, and detailed.
The incorporation of AI into biosensor technology is enhancing diagnostic precision and specificity, leading to a higher demand for such innovations and contributing to the market's growth.
The rising prevalence of infectious diseases is a significant global market driver. Infectious diseases require person-specific treatment, and immunoprotein diagnostic testing plays a vital role in providing accurate and timely diagnoses. The use of biomarker-based diagnostics ensures precise and targeted treatment.
Advancements in biomarker technologies are further boosting the growth of the global immunoprotein diagnostic testing industry. Cutting-edge developments in diagnostic techniques enable more precise and detailed disease data.
Such technological advancements contribute to the growing demand for accurate, timely, and specific diagnostic results, which are key drivers of the market's expansion.
The growing adoption of alternative diagnostic technologies significantly restrains the growth of the global market. These alternatives, including molecular diagnostics, imaging techniques, and biochemical assays, offer competitive options for disease diagnosis, creating a challenging environment for immunoprotein-based methods.
The widespread availability and adoption of such advanced technologies present strong competition to immunoprotein diagnostic methods, hindering their market growth and posing significant challenges to industry players.
Strategic collaborations among market players are fostering innovation and driving market growth by enabling the launch of advanced products that combine individual technological expertise. Such partnerships aim to leverage complementary strengths, enhancing diagnostic capabilities and expanding market opportunities.
These collaborations create an environment ripe for innovation, advancing immunoprotein diagnostic technologies and accelerating the market's growth trajectory.
Kits & reagents segment dominates the market with the largest market revenue. The kits and reagents segment holds the largest revenue share due to its cost-effectiveness compared to instruments. Kits and reagents offer a more affordable option for diagnostic procedures, lowering the overall cost of testing. This affordability makes them highly accessible and widely adopted in healthcare settings.
Request Customizationto receive a tailored report.
Enzyme immunoassay segment dominates the market with the largest market revenue. The enzyme immunoassay (EIA) segment dominates the market owing to its high sensitivity, specificity, ease of automation, and affordability. Technological advancements in this segment continue to improve diagnostic accuracy and efficiency.
This innovation highlights the segment's growth potential through technological advancements.
Oncology segment dominates the market with the largest market revenue. The oncology segment generates the highest market revenue due to the increasing global prevalence of cancer and its significant mortality rate. Cancer remains the leading cause of death worldwide, driving the demand for precise diagnostic tools.
Diagnostic laboratories segment dominates the market with the largest market revenue. The diagnostic laboratories segment leads the market due to its specialization in disease diagnosis. These laboratories focus exclusively on diagnostic services, ensuring high specificity and accuracy in testing. Their role as key providers of healthcare diagnostics solidifies their dominance in the market. With a growing need for reliable diagnostic solutions, this segment continues to expand, providing critical services that support accurate disease management.
Speak to an Analystto discuss market opportunities.
North America holds the largest revenue share in the global market, driven by advanced healthcare infrastructure, substantial R&D investments, and a high prevalence of cancer and infectious diseases. For instance, the American Cancer Society estimates over 2 million new cancer cases in the U.S. in 2024.
Moreover, the region benefits from the presence of major industry players such as Agilent Technologies, Inc., Thermo Fisher Scientific Inc., PerkinElmer Inc., and Bio-Rad Laboratories, Inc., headquartered in the U.S. and Canada. These companies play a critical role in driving innovation and expanding diagnostic capabilities, further solidifying its dominance.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia-Pacific is poised to witness the fastest CAGR, fueled by rising incidences of cancer and infectious diseases coupled with the rapid development of healthcare infrastructure. Government initiatives to enhance healthcare systems and streamlined regulatory frameworks are accelerating regional growth. s
For example, the World Health Organization (WHO) reported 2.82 million TB cases in India, highlighting the urgent need for advanced diagnostic solutions. Countries like China, Japan, and India are leading this regional expansion, with increasing investments in healthcare technologies and diagnostic tools driving market growth.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
Flow Cytometry Market Size, Share, Growth, Analysis, Report, 2034
Gene Synthesis Market Size, Share, Growth, Analysis, Report, 2034
Cell Surface Markers Detection Market Size, Share, Growth, 2034
Single-Use Assemblies Market Size, Share, Growth, Analysis, 2034
Cancer Microbiome Sequencing Market Size, Share, Growth, 2034
Inhaled Biologics Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com